|[April 16, 2014]
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.
STEVENSON, Md. --(Business Wire)--
The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or
the "Company") (NasdaqCM: ZLCS) and other violations of state law by the
board of directors of Zalicus relating to the proposed merger of the
Company with Epirus Biopharmraceuticals, Inc. ("Epirus").
Under the terms of the transaction, the percentage of the combined
company that Zalicus shareholders will own as of the closing of the
merger is subject to an adjustment at closing based on the level of
Zalicus net cash at closing. If the merger were to close today, he
stockholders of Zalicus would own only 14% of the combined company.
The firm's investigation seeks to determine, among other things, whether
the Company's board of directors breached their fiduciary duties by
failing to maximize shareholder value before agreeing to enter into this
transaction, and whether Epirus is underpaying for Zalicus shares.
If you currently own common stock of Zalicus and would like to learn
more about the investigation being conducted by Brower Piven, without
cost or obligation to you, click here: http://www.browerpiven.com/currentinvestigations.html.
You may also request more information by contacting Brower Piven either
by email at firstname.lastname@example.org
or by telephone at (410) 415-6616. Attorneys at Brower Piven together
have more than a century of experience litigating securities and other
class action cases.
[ Back To Technology News's Homepage ]